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The aim of this research study was to elucidate the role of 
RANK, RANKL, and OPG in microglial responses to the pro-
inflammatory stimuli lipopolysaccharide (LPS) and polyino-
sinic-polycytidylic acid (Poly I:C). Here, we show that RANK 
signalling is important for regulating the activation of the 
BV2 microglial cell line. We found that LPS treatment causes 
a significant decrease in the expression of RANK in the BV2 
cell line while significantly increasing the expression of OPG, 
Toll-like receptor (TLR)3, and the adaptor proteins MyD88 
and TRIF. We found that pretreatment of BV2 cells with 
RANKL for 24 h before the LPS or Poly I:C exposure decreas-
es the expression of inflammatory markers such as inducible 
nitric oxide synthase and cyclooxygenase. This is accompa-
nied by a decreased expression of the TLR adaptor proteins 
MyD88 and TRIF, which we observed after RANKL treatment. 
Similar results were obtained in our experiments with pri-
mary mouse microglia. Using recently developed CRISPR/
Cas9 technology, we generated a BV2 cell line lacking RANK 
(RANK –/– BV2). We showed that most effects of RANKL pre-
treatment were abolished, thereby proving the specificity of 
this effect. Taken together, these findings suggest that 
RANK signalling is important for modulating the inflamma-
tory activation of microglial cells to a moderate level, and 
that RANK attenuates TLR3/TLR4 signalling. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Inflammation in the perinatal brain caused by maternal or 
intrauterine fetal infection is now well established as an im-
portant contributor to the development of perinatal brain 
injury. Exposure to inflammatory products can impair peri-
natal brain development and act as a risk factor for neuro-
logical dysfunction, cognitive disorders, cerebral palsy, or 
preterm birth. Pre-exposure to inflammation significantly 
exacerbates brain injury caused by hypoxic/ischaemic in-
sult. Tumour necrosis factor (TNF) is a family of cytokines 
largely involved in inflammation signalling. In our previous 
study, we identified the importance of TNF-related apopto-
sis-inducing ligand (TRAIL) signalling in the development of 
perinatal brain injury. We observed a significant increase in 
the expression levels of a soluble decoy receptor for TRAIL, 
osteoprotegerin (OPG). Besides TRAIL, OPG is able to bind 
the receptor activator of the NF-κB (RANK) ligand (RANKL) 
and inhibit its signalling. The function of the RANK/RANKL/
OPG system in the brain has not come under much scrutiny. 
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 Introduction 
 Microglial cells are the most abundant resident mac-
rophages in the central nervous system (CNS) and are the 
first line of defence against injury and infection. As a con-
sequence of brain injury or inflammatory stimuli, mi-
croglial cells respond by changing their phenotype from 
ramified morphology to an activated form. These activat-
ing stimuli can range from pathogens and pathogenic 
products to cytokines, or the efflux of intracellular con-
tents following injury  [1] . In the healthy brain, microglial 
cells are continually surveying their local micro-environ-
ment with their highly dynamic processes and are re-
sponsible for the elimination and refinement of synaptic 
connections. This microglial function is especially impor-
tant and pronounced during the development of the brain 
 [2] . The main function of the microglial cell in patholog-
ical situations is the clearance of the damaged cells after 
injury and phagocytosing and neutralizing infectious 
agents  [3] . Moreover, the activated microglia cells secrete 
a range of signalling cytokines into their surroundings in 
order to communicate with the rest of the cells in the 
brain. Cytokine secretion is aimed at guiding other im-
mune-competent cells to the site of injury/infection to 
destroy infected or damaged neurons and oligodendro-
cytes, but uncontrolled phagocytosis can cause a large 
amount of bystander damage to the healthy cells. Among 
the most important stimuli leading to microglial activa-
tion are lipopolysaccharides (LPS) from Gram-negative 
bacteria and double-stranded (ds)RNA from viruses. 
These are detected by Toll-like receptor (TLR)4 localized 
on the surface of the microglial cell and TLR3 localized in 
the endosomes  [4, 5] . The inflammatory signalling of ac-
tivated TLR3 and TLR4 is mediated by adaptor proteins 
such as myeloid-differentiation primary-response gene 
88 (MyD88) and TIR-domain-containing adaptor-in-
ducing interferon (IFN)-β (TRIF). MyD88 is involved in 
the signalling of all TLRs except TLR3, where TRIF is the 
main adaptor. The precise regulation of microglial activa-
tion is not fully understood and is believed to be depen-
dent on many different external and internal factors. The 
disruption of this regulation can contribute to the devel-
opment or aggravation of existing brain disorders like 
neurodegeneration  [6] , traumatic injury  [7] , and perina-
tal brain injury  [8] . Inflammation has been recognized as 
one of the key contributing factors for the development 
of cerebral palsy in term-born infants  [9] ; this association 
is supported by experimental data from animal models of 
foetal infection showing that LPS-exposed ovine foetuses 
develop white-matter damage similar to that seen in hu-
man infants  [10] . Both clinical and experimental evidence 
also suggest that systemic infection/inflammation can af-
fect cerebral vulnerability to a later insult such as hypox-
ia-ischaemia (HI) in term infants  [11] .
 In our previous work investigating the involvement of 
tumour necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL) signalling in the development of 
perinatal brain injury  [12] , we found a significant in-
crease in osteoprotegerin (OPG) expression in vivo  in an 
animal model of neonatal brain injury as well as in vitro 
in neurons and oligodendrocyte precursor cells (OPCs) 
subjected to TNF-α/IFN-γ treatment. OPG is a soluble 
decoy receptor member of the TNF family and is able to 
bind and inhibit both TRAIL and RANKL signalling 
 [13] . In TRAIL signalling, the inhibition caused by the 
increased levels of OPG may be protective, as the pro-
apoptotic role of TRAIL through binding with death re-
ceptor (DR)4 or DR5 in the CNS is well established  [14] 
including in the context of neonatal brain injury  [12] . 
Despite the fact that RANKL, its corresponding receptor 
RANK, and OPG are expressed in the brain tissue, little 
is known about the action of OPG in the inhibition of 
RANKL signalling in the CNS. The RANK/RANKL in-
teraction has been involved in regulating fever responses 
in females following inflammation  [15] . More impor-
tantly, the OPG/RANKL/RANK axis has been described 
as critical for the inflammatory response in ischaemic 
brains in mice. It was shown that enhanced RANKL/
RANK signalling in OPG − / − mice or treatment with re-
combinant RANKL in wild-type mice leads to the reduc-
tion of infarct volume and brain oedema via reduced 
post-ischaemic inflammation  [16] .
 Most of the studies on the mechanism of action of the 
RANK/RANKL/OPG interaction have been performed 
in the context of inflammation-dependent bone resorp-
tion  [17, 18] and, unlike TRAIL signalling, RANK activa-
tion from RANKL promotes the differentiation of osteo-
clast cells  [19, 20] . As microglia and osteoclasts have a 
shared embryological origin (they both differentiate from 
common premonocyte lineage  [21] ) and display many 
characteristics typical of macrophages, this makes mi-
croglia obvious candidates for the action of RANK/
RANKL/OPG signalling in the brain.
 The aim of this study was to elucidate the mechanism 
of RANK, RANKL, and OPG in the regulation of microg-
lial responses to LPS and polyinosinic:polycytidylic acid 
(Poly I:C). We hypothesized that RANK/RANKL signal-
ling influences microglial activation in the brain by at-
tenuating the expression levels of the key components of 
TLR signalling.
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 Materials and Methods 
 Primary Microglia 
 Primary microglia were prepared from newborn Sprague-
Dawley rats as described previously  [22, 23] . In brief, brain cortices 
were dissected from the rat pups on postnatal day (P)0–2, roughly 
chopped, and enzymatically digested with DNase I and 0.25% tryp-
sin-EDTA. Cells were resuspended in minimum essential Eagle’s 
medium supplemented with 10% FBS, 2 m M  L -glutamine, 100 μg/
mL penicillin-streptomycin solution (all from Sigma), and 0.6% 
glucose, and plated in T75 flasks at a density of 2 × 10 5 /cm 2 . Mixed 
glial cell cultures were grown for 11 days, and the microglia were 
separated from the OPCs and astrocytes through shaking. The 
mixed glial cell culture was shaken for 1.5 h at 260 rpm to detach 
the microglia from the layer of attached OPCs and astrocytes. Pu-
rified microglia were plated in DMEM supplemented with 10% 
FBS and 100 μg/mL penicillin-streptomycin solution (all from Sig-
ma).
 BV2 Cell Culture 
 The immortalized microglia cell line, BV2, was donated by Pro-
fessor R. Donato (University of Perugia, Perugia, Italy); it was gen-
erated by infecting primary mouse microglia cultures with a v-
raf/v-myc oncogene-carrying retrovirus (J2)  [24] . BV2 cells were 
cultured in RPMI medium containing 100 μg/mL penicillin-strep-
tomycin solution (both from Sigma) and supplemented with 10% 
FBS. Pilot experiments to determine the correct cell density to pre-
vent overcrowding and standardize treatments across plate types 
were performed. All experiments were repeated on at least 3 sepa-
rate occasions, representing separate experimental days at least 1 
passage apart. Activation of BV2 cells was achieved by treatment 
with LPS or Poly I:C (Sigma) at final concentrations of 10 ng/mL 
and 10 μg/mL, respectively. RANKL treatment was performed us-
ing recombinant murine RANKL (200 ng/mL; Peprotech Inc., 
USA), with the concentration chosen after previous optimization 
experiments (data not shown).
 RT-qPCR 
 For analysis of the expression levels of target genes, the cells 
were solubilized in DireCtQuant 100 (Spain) and processed ac-
cording to the manufacturer’s instructions. Before the real-time 
quantitative PCR (RT-qPCR) reactions, the samples were treated 
with dsDNase (ThermoFisher Scientific, UK) according to the 
manufacturer’s instructions to remove the double-genomic DNA. 
The reverse-transcription reaction was performed using an Ame-
thyst One-Step RT-kit with ROX and SYBR (Cambridge Biosci-
ence) or TaqMan ® RNA-to-Ct TM 1-Step kit according to the man-
ufacturer’s instructions. RT-qPCR experiments were performed 
using the StepOnePlus TM Real-Time PCR Systems (ThermoFisher 
Scientific). The TaqMan probes for TLR3, RANK, and GAPDH 
were purchased from ThermoFisher Scientific and the primers 
from Integrated DNA Technologies ( Table 1 ). All reactions were 
conducted in duplicate and corrected to the expression of the in-
ternal control genes GAPDH, actin-β, and RNA polymerase II 
polypeptide A. Data was analyzed using the delta threshold cycle 
(CT) method  [25] .
 RANK Gene Knockout 
 The RANK receptor gene was excised from the BV2 genome 
using CRISPR-Cas9 genome editing ( Fig.  1 ). BV2 cells were co-
SYBR primers  
Mouse TRIF_F GCC AGC CAC CTA GAG ATC AG
Mouse TRIF_R TGT CCA GCG GTG TGT TAC AT
Mouse TLR4_F GCT CCT GGC TAG GAC TCT GA
Mouse TLR4_R TGT CAT CAG GGA CTT TGC TG
Mouse MyD88_F CAC CTG TGT CTG GTC CAT TG
Mouse MyD88_R AGG CTG AGT GCA AAC TTG GT
Mouse GAPDH_F GGT GCT GAG TAT GTC GTG GA
Mouse GAPDH_R CAC ACC CAT CAC AAA CAT GG
Rat RANK_F GTGCTGGAGTCTGTGGACCT
Rat RANK_R CCGGTCCGTGTACTCATCTT
Mouse RANK_Genot_F CCT CCG ACA GTG TGT GTC TG
Mouse RANK_Gento_R CAG ACT TTA TGC AGC AAG CA
Puromycin_Seq_F CTT CAC CGT CAC CGC C
18S_RNA_F CGC GGT TCT ATT TTG TTG GT
18S_RNA_R AGT CGG CAT CGT TTA TGG TC
Taqman probes  
Mouse OPG Mm01205928_m1
Mouse RANKL Mm00441906_m1
Mouse RNA polymerase II polypeptide A Mm00839502_m1
Mouse iNOS Mm00440502_m1
Mouse TLR3 Mm01207404_m1
Mouse RANK Mm00437132_m1
Rat RANKL Rn00589289_m1
Rat OPG Rn00563499_m1
Rat β-actin Rn00667869_m1
 Table 1.  Primer sequence and Taqman 
probe reference numbers used in the 
study
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transfected with Cas9 and homologous directed repair (HDR) plas-
mids using Ultracruz transfection reagent and plasmid transfection 
medium (all from Santa Cruz Biotechnology). Cas9 plasmid carries 
the gene for Cas9 enzyme synthesis, an RNA guide sequence, and 
for green fluorescent protein (GFP) expression. The RNA guide 
sequence consists of a 20-nucleotide sequence complementary to 
the mouse RANK gene (guide sequence) and a loop for the recogni-
tion and binding of the Cas9 enzyme. When in complex, the RNA 
guide and the Cas9 enzyme are capable of performing dsDNA 
cleavage at a precise place in the target gene, in this case, the first 
exon of  RANK . GFP encoded by the Cas9 plasmid is used as posi-
tive control for the transfection, allowing transfected cells to be vi-
sualized by fluorescence microscopy 24 h after the transfection. The 
HDR plasmid carries the sequence used as a template for HDR of 
the dsDNA cleavage generated by Cas9. This template sequence is 
flanked by the 3 ′ and 5 ′ arms complementary to the  RANK gene; 
these direct the sequence to the precise place of the DNA break. The 
template sequence between the 2 arms is inserted into the  RANK 
gene, breaking the first exon and rendering the gene inactive. The 
inserted sequence consists of gene coding for red fluorescent pro-
tein (RFP) and the puromycin resistance gene flanked by LoxP 
sites. RFP expression allows the visualization of the transfected cells 
by fluorescence microscopy and the puromycin resistance gene is 
used to select the positive cells by plating them on media supple-
mented with 5 μg/mL puromycin. The LoxP sites allow the remov-
al of RFP and puromycin genes from the cell DNA while preserving 
the target gene breakage. The cells were visualized using EVOS FL 
cell imaging system (ThermoFisher Scientific).
 Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism v5.0 
software. Data is expressed as mean ± standard error of the mean 
(SEM). Comparisons between the experimental groups were made 
using one-way analysis of variance (ANOVA) followed by the 
Dunnett test (treatment conditions vs. control) or the Tukey test 
(treatment vs. control and vs. another treatment).
 Results 
 TNF-α/INF-γ Treatment and Oxygen-Glucose 
Deprivation Inhibit RANK Signalling by Decreasing 
RANK/RANKL Expression in the Primary Microglia 
 Previously, we showed that the expression levels of 
OPG mRNA increased significantly after HI injury in P9 
mice  [12] . We also found a significant upregulation of 
OPG mRNA expression in the primary neurons after 
oxygen-glucose deprivation (OGD) and/or TNF-α/
INF-γ treatment and also in the OPCs after TNF-α/
INF-γ treatment  [12] . The fact that OPG expression is 
increased suggests that RANK signalling is inhibited;
increased levels of OPG will outcompete RANK for 
RANKL binding.
 In this study, we initially determined whether the ex-
pression levels of OPG, RANK, and RANKL were changed 
in microglial cells after the HI and/or inflammatory in-
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 Fig. 1. Generating RANK knockout using the CRISPR/Cas9 sys-
tem. Schematic representation of the double-transfection with 
Cas9 and HDR plasmids, the binding of the Cas9 enzyme to guide 
RNA with consecutive double-strand cleavage in the  RANK gene, 
and the introduction of the LoxP/RFP/Puro/LoxP sequence from 
the HDR plasmid through homologous directed repair. 
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 Fig. 2. The effect of OGD and/or TNF-α/INF-γ treatment on the 
expression levels of OPG, RANKL, and RANK in primary rat mi-
croglia, measured 24 h after the treatment. Bars, mean; error bars, 
SEM. Results are expressed as fold change compared with non-
treated control cells;  *   p < 0.05;  * *   p < 0.01;  * * *   p < 0.001.  n = 5. 
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sult. We performed in vitro  experiments with primary 
microglia subjected to OGD to mimic HI and with TNF-
α and INF-γ to mimic inflammatory insult. The mRNA 
expression of OPG, RANK, and RANKL was measured 
48 h after the insult, and we found that the expression in-
creased significantly only when the OGD and TNF-α/
INF-γ treatment were combined ( Fig. 2 ). However, the 
change in the expression levels of RANK and RANKL was 
much more dramatic. OGD and TNF-α/INF-γ treat-
ments both reduced the expression of RANK and RANKL, 
and, in combination, they reduced the expression to 6% 
(for RANK) and 3% (for RANKL) of their normal expres-
sion levels. We speculated that this reduction, together 
with the general increase of OPG expression after insult, 
shuts down RANKL signalling in the microglial cells, and 
that this happens when the cells shift to a pro-inflamma-
tory phenotype.
 RANKL Pretreatment Prevents an Increase in 
Inflammatory Markers in BV2 Cells Caused by LPS 
and Poly I:C Treatment 
 As the transfection of the primary microglia usually 
produces a very low number of transfected cells and the 
generation of knockout primary cell culture is not feasi-
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 Fig. 3. Expression levels of the inflammatory markers iNOS and 
COX2 in the BV2 cell line after RANKL pretreatment and LPS or 
Poly I:C treatment. BV2 cells were pretreated with 200 ng/mL re-
combinant RANKL for 24 h before the treatment with 10 ng/mL 
LPS ( a ,  c ) or 10 μg/mL Poly I:C ( b ,  d ). mRNA levels of iNOS ( a ,  b ) 
and COX2 ( c ,  d ) were measured 6 h later by RT-qPCR and normal-
ized with respect to the reference gene  GAPDH . Bars, mean; error 
bars, SEM. Results are expressed as fold change compared with 
non-treated control cells. Statistical significance was calculated 
with respect to non-treated controls ( * *   p < 0.01;  * * *   p < 0.001) or 
LPS/Poly I:C non-RANKL-treated cells ( #   p < 0.05;  ###   p < 0.001). 
 n = 4. 
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ble, we decided to use the mouse microglial cell line BV2 
in order to further clarify the role of RANK signalling in 
the development of an inflammatory phenotype of mi-
croglial cells. The BV2 cell line has been reported as a 
valid substitute for primary microglia in many experi-
mental settings  [26] and is widely used in in vitro experi-
ments. These cells are highly responsive to inflammatory 
stimuli like LPS and Poly I:C, which cause a significant 
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increase in the expression of inflammatory markers such 
as inducible nitric oxide synthase (iNOS,  Fig. 3 a, b) and 
cyclooxygenase (COX)2,  Fig. 3 c, d). We pretreated BV2 
cells with recombinant RANKL for 24 h before exposure 
to LPS and Poly I:C and measured the mRNA expression 
levels 6 h later. RANKL pretreatment was able to signifi-
cantly decrease the expression level of COX2 after LPS 
and Poly I:C insult compared with cells treated with ve-
hicle only ( Fig. 3 c, d). The pretreatment was able to sig-
nificantly reduce the expression of iNOS with LPS treat-
ment ( Fig. 3 a) but not when the cells were treated with 
Poly I:C ( Fig. 3 b). The results showed that the activation 
of RANK by RANKL renders the BV2 cells less reactive 
to LPS and Poly I:C.
 RANKL Pretreatment Restricts the Increase in TLR3 
Expression Caused by LPS and Poly I:C Exposure 
 Given our previous results, we investigated the possi-
ble mechanism of the inhibition of inflammatory pheno-
type caused by RANKL pretreatment. We hypothesized 
that RANKL pretreatment would reduce the expression 
levels of the key proteins responsible for the recognition 
of LPS and Poly I:C. We therefore assessed the mRNA 
expression levels of TLR3 (recognizing Poly I:C) and 
TLR4 (recognizing LPS), in response to the inflammatory 
stimuli after the RANKL pretreatment. We found that 
both the LPS and the Poly I:C treatment resulted in a sig-
nificant increase in TLR3 expression ( Fig. 4 a, b), while 
TLR4 expression remained unaffected ( Fig.  4 c, d). 
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in the BV2 cell line after RANKL pretreatment and LPS or Poly I:C 
treatment. BV2 cells were pretreated with 200 ng/mL recombinant 
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 Fig. 6. Expression levels of inflammatory markers iNOS, COX2 of 
adaptor proteins MyD88 and TRIF, and TLR3 in primary mouse 
microglia after RANKL pretreatment and Poly I:C treatment. Pri-
mary mouse microglia cells were pretreated with 200 ng/mL re-
combinant RANKL for 24 h before the treatment with 10 μg/mL 
Poly I:C. mRNA levels of iNOS ( a ), COX2 ( b ), MyD88 ( c ), TRIF 
( d ), and TLR3 ( e ) were measured 6 h later by RT-qPCR and nor-
malized with respect to the reference gene  GAPDH . Bars, mean; 
error bars, SEM. Results are expressed as fold change compared 
with non-treated control cells. Statistical significance was calcu-
lated with respect to non-treated controls ( * *   p < 0.01) or Poly I:C-
treated non-RANKL-treated cells ( #   p < 0.05).  n = 3. 
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RANKL pretreatment significantly restricted the upregu-
lation of TLR3 caused by both the LPS and Poly I:C treat-
ments ( Fig.  4 a, b). Interestingly, the RANKL pretreat-
ment did not affect the basal levels of TLR3 expressed 
when the BV2 cells were not challenged by an inflamma-
tory stimulus. In addition, we assessed the RANK recep-
tor to determine whether expression can be reduced by 
either LPS or Poly I:C, the same way as they are reduced 
in the microglia by TNF-α/INF-γ. We found that LPS 
( Fig. 4 e), but not Poly I:C ( Fig. 4 f), reduced the mRNA 
level of RANK. RANKL pretreatment did not influence 
the reduction in RANK expression caused by LPS ( Fig. 4 e).
 RANKL Pretreatment Prevents the Increased 
Expression of the Adaptor Proteins MyD88 and TRIF 
Caused by LPS and Poly I:C Treatment 
 Following the binding of the ligand to TLR3 and TLR4, 
propagation of the inflammatory signal requires the re-
cruitment of the adaptor proteins MyD88 and TRIF. We 
assessed changes in expression after an inflammatory 
challenge, and found that LPS and Poly I:C increased the 
expression levels of both MyD88 ( Fig. 5 a, b) and TRIF 
( Fig. 5 c, d). Pretreatment with RANKL attenuated the in-
creases in MyD88 and TRIF expression after both LPS 
and Poly I:C treatment.
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 Fig. 7. Generation of RANK knockout BV2 
cell line.  a Schematic representation of the 
process of generation of the homo-knock-
out RANK BV2 cell line.  b Fluorescent live 
imaging of BV2 cells transfected with Cas9 
and HDR plasmids; 48 h after the transfec-
tion, green cells (expressing GFP from the 
Cas9 plasmid) and red cells (expressing 
RFP from the HDR plasmid) can be seen.
 c Fluorescent live imaging of puromycin-
selected clones of BV2 cells; 1 week after 
the transfection, all cells are expressing 
RFP from the HDR plasmid construct in-
troduced into the cell genomic DNA.
 d qPCR verification of the deletion in the 
 RANK gene after the first transfection; nor-
mal BV2 cells (RANK wtBV2; blue line) 
with CT = 29.00, Cas9/HDR-transfected 
BV2 (RANK cas9BV2; purple line) CT = 
30.60, and the control reactions with the 
18S RNA gene normal BV2 cells (18S 
wtBV2; magenta line) CT = 28.77, Cas9/
HDR-transfected BV2 (18S cas9BV2; or-
ange line) CT = 29.05. 
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 RANKL Pretreatment Modulates MyD88 Expression 
in the Primary Microglia 
 Although the BV2 cell line mimics many of the prop-
erties of microglia, we confirmed the effects of RANKL 
pretreatment in primary mouse microglia cultures ex-
posed to Poly I:C ( Fig. 6 ). We observed a significant inhi-
bition of Poly I:C-induced MyD88 overexpression if the 
culture was pretreated with RANKL ( Fig. 6 c). We also ob-
served a trend towards the inhibition of iNOS ( Fig. 6 a), 
TRIF ( Fig. 6 d), and TLR3 ( Fig. 6 e) overexpression in the 
same experiment.
 Development of a Stable BV2 RANK –/– Cell Line Using 
CRISPR/Cas9 Technology 
 In order to verify that the effects observed after RANKL 
pretreatment were caused by the activation of the RANK 
signalling pathway, we generated a BV2 cell line lacking 
the RANK receptor (BV2 RANK –/– ) using CRISPR/Cas9 
technology. This RANK knockout BV2 cell line was gen-
erated by co-transfecting the cells with HDR and Cas9 
plasmids ( Fig. 7 a). In the first 24–48 h after co-transfec-
tion, the cells successfully transfect with Cas9 plasmid 
display green fluorescence, and in the next 24-48 h, the 
green fluorescence is gradually lost and substituted by red 
fluorescence in the cells where the double-transfection 
with Cas9 and HDR plasmids has been successful ( Fig. 7 b). 
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 Fig. 8. Expression levels of inflammatory markers iNOS and COX2 
in the RANK –/– BV2 cell line after RANKL pretreatment and LPS 
or Poly I:C treatment. RANK –/– BV2 cells were pretreated with 200 
ng/mL recombinant RANKL for 24 h before the treatment with 10 
ng/mL LPS ( a ,  c ) or 10 μg/mL Poly I:C ( b ,  d ). mRNA levels of iNOS 
( a ,  b ) and COX2 ( c ,  d ) were measured 6 h later by RT-qPCR and 
normalized with respect to the reference gene  GAPDH . Bars, 
mean; error bars, SEM. Results are expressed as fold change com-
pared with non-treated control cells. Statistical significance was 
calculated with respect to non-treated controls ( * * *   p < 0.001) or 
LPS/ Poly I:C-treated cells.  n = 6 for control and RANK;  n = 3 for 
LPS, Poly I:C, RANKL + LPS, and RANKL + Poly I:C. 
 Kichev/Eede/Gressens/Thornton/Hagberg
 
 Dev Neurosci 2017;39:192–206 
DOI: 10.1159/000464244
202
Cells with genomic (permanent) insertion of the puromy-
cin resistance gene were positively selected for growth in 
puromycin-supplemented medium. The selected cells 
display intensive red fluorescence ( Fig. 7 c).
 We picked 4 different BV2 colonies and analyzed them 
by direct DNA sequencing (Beckman Coulter Genomics, 
UK) with sequencing primers generated from the puro-
mycin gene (Puromycin_Seq_F;  Table 1 ). Based on the 
information from the sequencing, we designed a set of 
primers (Mouse RANK_Genot_F and Mouse RANK_
Genot_F;  Table 1 ) with the reverse primer spanning the 
site of the HDR insert. Using this set of genotyping prim-
ers, we verified the  RANK gene knockout by qPCR. The 
CT values calculated for the cells with both  RANK genes 
intact was around 30, while the cells carrying only 1 intact 
copy of the  RANK gene showed CT values of approxi-
mately 31 ( Fig. 7 d). The gene for 18S ribosomal RNA was 
used as a control for the total amount of genomic DNA 
in the reaction  [27] . Unfortunately, all 4 colonies selected 
were heterozygous; only 1 of the  RANK genes cleaved 
while preserving the intact gene in the other homologous 
chromosome. For this reason, we transduced one of the 
clones with the Cre recombinase gene-carrying adenovi-
rus VQAd Cre (ViraQuest, USA). The Cre recombinase 
excised the RFP and puromycin genes from the cell ge-
nome, making the cells sensitive to puromycin and non-
fluorescent again. After selecting non-fluorescent cells, 
we performed a second double-transfection with Cas9 
and HDR plasmids ( Fig. 7 a). The colonies selected after 
the second transformation were double knockouts for the 
 RANK gene, verified by a non-detectable signal using our 
qPCR assay.
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 Fig. 9. Expression levels of TLR3 and TLR4 in the RANK –/– BV2 
cell line after RANKL pretreatment and LPS or Poly I:C treatment. 
RANK –/– BV2 cells were pretreated with 200 ng/mL recombinant 
RANKL for 24 h before the treatment with 10 ng/mL LPS ( a ,  c ) or 
10 μg/mL Poly I:C ( b ,  d ). mRNA levels of TLR3 ( a ,  b ) and TLR4 
( c ,  d ) were measured 6 h later by RT-qPCR and normalized with 
respect to the reference gene  GAPDH . Bars, mean; error bars, SEM. 
Results are expressed as fold change compared with non-treated 
control cells. Statistical significance was calculated with respect to 
non-treated controls ( * *   p < 0.01;  * * *   p < 0.001) or LPS/Poly I:C 
non-RANKL-treated cells ( ##    p < 0.01).  n = 6 for control and 
RANK;  n = 3 for LPS, Poly I:C, RANKL + LPS, and RANKL + 
Poly I:C. 
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 Knocking out the RANK Receptor from BV2 
Cells Abolishes the Anti-Inflammatory Effect of 
Recombinant RANKL Pretreatment 
 To characterize our new BV2 RANK –/– cell line, we 
first explored the response of the inflammatory markers 
iNOS and COX2 to inflammatory LPS or Poly I:C in the 
presence and absence of RANKL pretreatment. Unlike 
the previous BV2 results ( Fig. 3 ), the RANKL pretreat-
ment was unable to prevent the significant upregulation 
of iNOS and COX2 caused by both LPS ( Fig. 8 a, c) and 
Poly I:C ( Fig. 8 b, d). This finding confirms that RANK is 
essential for the reduction in the expression of inflamma-
tory markers observed in the BV2 wild-type mice cells 
due to RANKL pretreatment.
 Knocking out the RANK Receptor from BV2 Cells 
Does Not Alter the Inhibition of TLR3 Expression 
Caused by RANKL Pretreatment 
 As previously, we assessed the expression levels of 
TLR3 and TLR4 in the BV2 RANK –/– cell line after the 
RANKL pretreatment followed by LPS and Poly I:C. In-
terestingly, unlike with the inflammatory markers iNOS 
and COX2, here the significant decrease in the expression 
of TLR3 after RANKL pretreatment was not abolished
by the removal of the RANK receptor ( Fig. 9 a, b). This 
may suggest an alternative unreported receptor with a 
RANKL-specific affinity for TLR3 signalling. TLR4 ex-
pression remained unaffected ( Fig. 9 c, d).
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 Fig. 10. Expression levels of adaptor proteins MyD88 and TRIF in 
the RANK –/– BV2 cell line after RANKL pretreatment and LPS or 
Poly I:C treatment. RANK –/– BV2 cells were pretreated with 200 
ng/mL recombinant RANKL for 24 h before the treatment with 10 
ng/mL LPS ( a ,  c ) or 10 μg/mL Poly I:C ( b ,  d ). mRNA levels of 
MyD88 ( a ,  b ) and TRIF ( c ,  d ) were measured 6 h later by RT-qPCR 
and normalized with respect to the reference gene  GAPDH . Bars, 
mean; error bars, SEM. Results are expressed as fold change com-
pared with non-treated control cells. Statistical significance was 
calculated with respect to non-treated controls ( *   p < 0.05;  * *   p < 
0.01;  * * *   p < 0.001).  n = 6 for control and RANK;  n = 3 for LPS, 
Poly I:C, RANKL + LPS, and RANKL + Poly I:C. 
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 BV2 RANK –/– Cells Are Resistant to the Reduction in 
Expression of the Adaptor Proteins MyD88 and TRIF 
Caused by RANKL Pretreatment 
 The expression levels of the adaptor proteins MyD88 
and TRIF were studied in experiments performed with 
BV2 RANK –/– cells. Here again, as with the inflammatory 
markers iNOS and COX2, the absence of the RANK recep-
tor completely abolished the effect of RANKL pretreatment 
over the expression levels of MyD88 and TRIF ( Fig. 10 ).
 Discussion 
 In this study, we showed a possible mechanism for the 
regulation of the microglial responses to LPS and Poly I:C 
by the RANKL/RANK pathway. We propose that there is 
an antagonistic relationship between TLR3/TLR4 signal-
ling and RANK signalling ( Fig.  11 ). The activation of 
TLR4 by LPS suppresses the expression of the RANK re-
ceptor in a similar way to TNF-α/INF-γ treatment. LPS 
treatment concomitantly increases the expression of 
TLR3 and the adaptor proteins MyD88 and TRIF. A sim-
ilar activation of TLR3 by Poly I:C was observed, with the 
exception of the suppression of RANK expression. In-
creased levels of TLR3, MyD88 and TRIF suggest that the 
cells are becoming more susceptible to consecutive in-
flammatory stimuli, and this may result in a self-perpet-
uating increase of the inflammation response ( Fig. 11 a).
 At the same time, the inhibition of RANK signalling 
after HI insult in the neonatal mouse brain caused by 
overexpression of the decoy receptor OPG  [12] is not re-
stricted only to the microglial cells, as OPG is markedly 
overexpressed in primary neurons. In primary microglia 
treated with the inflammatory cytokines TNF-α/INF-γ or 
subjected to OGD, the levels of RANK and RANKL were 
significantly decreased ( Fig. 2 ). A similar decrease in the 
expression of RANK in the BV2 cells was observed after 
the treatment with LPS ( Fig. 4 e). All these changes sug-
gest that, during inflammation, the OPG/RANKL ratio 
shifts in favour of OPG and, as a consequence, the level of 
free RANKL able to bind the RANK receptor will de-
crease significantly. This, combined with the significant 
decrease in the RANK receptor in microglial cells, sug-
gests a significant decrease in RANK signalling in the mi-
croglial cells. Previous studies have identified the impor-
tance of the RANK signalling pathway in inflammation 
in the ischaemic brain. In an adult mouse model of HI, 
animals lacking OPG (OPG –/– ) experienced a reduction 
in infarct volume accompanied by reduced post-isch-
aemic inflammation  [16] . In the same study, the authors 
showed that enhancing RANKL/RANK signalling in 
wild-type animals by recombinant RANKL is able to sig-
nificantly reduce the infarct volume.
 In our experiments, pretreatment of BV2 cells with re-
combinant RANKL decreased the ability of TLR3/TLR4 
signalling to activate the expression of TLR3, MyD88, and 
TRIF. This suppressed BV2 microglia activation, con-
firmed by the reduction of the inflammatory markers 
iNOS and COX2. In addition, our previous work suggest-
ed that MyD88 plays a pivotal role in LPS-induced sensi-
tization to HI, resulting in the potentiation of neonatal 
brain injury  [28] . Therefore, keeping the expression of 
adaptor proteins at physiological levels by RANK activa-
tion is important to prevent the overactivation of TLR sig-
nalling in microglial cells. All the effects of recombinant 
RANKL treatment are present only if cells are treated pri-
or to the inflammatory insult. In our experiments we 
failed to observe any effect if the cells were treated with 
RANKL after/at the same time as LPS and Poly I:C (data 
not shown). This may be due to a much faster metabolic 
reaction to the inflammatory stimuli shutting down the 
RANK signalling (including the downregulation of RANK 
expression;  Fig. 4 e), thus preventing the action of RANKL.
 Another interesting finding was the ability of LPS treat-
ment to significantly increase the expression of TLR3 and 
the TRIF adaptor, which suggests that the activation of 
TLR4 can render the microglial cells more sensitive to
dsRNA/Poly I:C. On the other hand, the activation of 
TLR3 was able to increase the expression of the MyD88 
adaptor but not of TLR4. As MyD88 is the adaptor protein 
for all TLRs (except for TLR3) this may suggest that the 
activation of either TLR3 or TLR4 will increase the sensi-
tivity of the microglial cells to inflammatory stimuli in gen-
eral.
 The removal of the RANK receptor from BV2 cells 
abolished the effect of RANKL pretreatment, except for 
the increase in TLR3 expression caused by the LPS and 
Poly I:C treatment. This unexpected finding can be attri-
buted to an undescribed alternative receptor of RANKL. 
As most of the TNF receptor family members are similar 
in structure, it is not unlikely that RANKL binds and ac-
tivates another receptor of the same family with a lower 
affinity, in the same way that OPG is able to bind both 
RANKL and TRAIL, or TNF-α and lymphotoxin-α both 
bind TNF receptor-1 and TNF receptor-2  [29] .
 The method of generating the RANK knockout BV2 
cell line described in this paper using commercial
CRISPR/Cas9 technology is a relatively cheap and quick 
way of generating genetically modified cells. Compared 
with traditional ways of decreasing the expression levels 
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of certain proteins using siRNA, here we had 100% re-
moval of the target protein in all cells in our culture which 
was maintained through subsequent passages in the cell 
line. The precision of the CRISPR/Cas9 in targeting the 
desired gene substantially decreases the chances of off-site 
effects. Because of all these features, the results we ob-
tained were very reliable and reproducible. This technol-
ogy can be used as a valuable tool for proof-of-concept as 
well as for studying the effect of single or multiple gene 
knockouts in a cell line. The convenient production of 
both homo- and hetero-knockout clones using this tech-
nique and the use of the same cell line for multiple-gene 
manipulation makes this system a valuable tool for in vitro 
research. Special attention should be focussed on the fact 
LPSRANKL
OPG
RANK
MyD88
TLR4
Poly I:C
TLR3
TRIF
RANK
RANK MyD88 TRIF TLR3
TLR3
TRIF
MyD88 TRIF TLR3
LPS
RANKL
RANK MyD88
TLR4
Poly I:C
a
b
 Fig. 11.  Antagonistic action of TLR3/TLR4 
signalling and RANK signalling.  a Activa-
tion of TLR4 suppresses the expression of 
the RANK receptor and increases the ex-
pression of TLR3 and the adaptor proteins 
MyD88 and TRIF. A similar action of TLR3 
activation was observed, with the exception 
of the suppression of RANK. This mecha-
nism results in a self-perpetuating increase 
of the inflammation.  b Pretreatment of 
BV2 cells with recombinant RANKL de-
creases the ability of TLR3/TLR4 signalling 
to activate the expression of TLR3, MyD88, 
and TRIF. This suppresses BV2 microglia 
activation, confirmed by the reduction of 
the inflammatory markers iNOS and 
COX2. 
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that many of the cell lines available are polypoid and >2 
rounds of transfection may be needed in order to achieve 
the full removal of the target gene from the genome.
 To summarize our findings, we conclude that RANK 
signalling plays an important role in the regulation of mi-
croglial responses to inflammatory stimuli. The blockage 
of this signalling pathway may lead to the overstimulation 
of microglial cells, and, as a consequence, exacerbate 
damage after brain injury. In contrast, the initiation of 
RANK signalling decreases the inflammatory response 
and has the potential to be used as a treatment after brain 
injury. This study is the first to implicate RANK signal-
ling in the regulation of perinatal brain injury. More stud-
ies are therefore needed to fully understand the impact of 
RANK signalling.
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